10x Genomics, Inc. (BMV:TXG)

Market Cap	54.38B +171.1%
Revenue (ttm)	11.52B +2.3%
Net Income	-408.43M
EPS	-3.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Average Volume	913
Open	335.54
Previous Close	332.00
Day's Range	335.54 - 335.54
52-Week Range	150.00 - 363.00
Beta	n/a
RSI	28.25
Earnings Date	May 7, 2026

About 10x Genomics

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2012
• Employees: 1,178
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: TXG

Financial Performance

In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.

Financial numbers in USD